Product Description
Apremilast is used to treat psoriatic arthritis (a condition that causes joint pain and swelling and scales on the skin). It is also used to treat moderate to severe plaque psoriasis (skin disease in which red, scaly patches form on some areas of the body) in people who may benefit from medications or phototherapy (a treatment that involves exposing the skin to ultraviolet light). Apremilast is used to treat ulcers in the mouth in people with Behcet's syndrome (a disorder that causes blood vessel swelling in the body). Apremilast is in a class of medications called phosphodiesterase inhibitors. It works by blocking the action of certain natural substances in the body that cause inflammation. (Sourced from: https://medlineplus.gov/druginfo/meds/a614022.html)
Mechanisms of Action: PDE4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Colombia | Croatia | Cyprus | Czech | Denmark | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Belgium, Canada, China, Czech Republic, France, Germany, Greece, India, Israel, Italy, Japan, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Russia, South Africa, Spain, Switzerland, Turkey, United Kingdom, United States
Active Clinical Trial Count: 33
Highest Development Phases
Phase 3: Arthritis|Arthritis, Juvenile|Arthritis, Psoriatic|Behcet Syndrome|Epididymitis|Oral Ulcer|Palmoplantar Psoriasis|Palmoplantar Pustulosis|Psoriasis|Skin Ulcer|Stomatitis, Aphthous
Phase 2: Dermatitis, Atopic|Hidradenitis Suppurativa|Lichen Planus
Phase 1: Alcoholism
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT05767047 | P3 |
Recruiting |
Arthritis, Juvenile|Behcet Syndrome|Oral Ulcer|Arthritis, Psoriatic |
2036-03-28 |
|
| 20190531 | P3 |
Unknown Status |
Oral Ulcer|Arthritis|Skin Ulcer|Epididymitis |
2032-12-30 |
|
| 2022-003024-41 | P3 |
Active, not recruiting |
Arthritis, Psoriatic|Arthritis, Juvenile |
2032-12-24 |
|
| PEAPOD | P3 |
Recruiting |
Arthritis, Juvenile|Arthritis, Psoriatic |
2030-10-18 |